637
Participants
Start Date
August 30, 2011
Primary Completion Date
September 9, 2015
Study Completion Date
September 9, 2015
Secukinumab (AIN457)
AIN457 (Secukinumab) is a human monoclonal antibody. Secukinumab binds and reduces the activity of Interleukin 17 (IL- 17). AIN457 was given as i.v. (10mg/kg) at baseline, week 2 and week 4, and then s.c. (75 or 150mg) every 4 weeks starting at week 8.
Placebo
Placebo was given as i.v. at baseline, week 2 and week 4, and then s.c. every 4 weeks starting at week 8.
Novartis Investigative Site, Budapest
Novartis Investigative Site, Budapest
Novartis Investigative Site, Brussels
Novartis Investigative Site, Eger
Novartis Investigative Site, Genk
Novartis Investigative Site, San Miguel de Tucumán
Novartis Investigative Site, Szolnok
Novartis Investigative Site, Gyula
Novartis Investigative Site, Ghent
Novartis Investigative Site, Bangkok
Novartis Investigative Site, Bangkok
Novartis Investigative Site, Bangkok
Novartis Investigative Site, Mexico City
Novartis Investigative Site, Pittsburgh
Novartis Investigative Site, Wheaton
Novartis Investigative Site, Mexicali
Novartis Investigative Site, Mexicali
Novartis Investigative Site, Durham
Novartis Investigative Site, Charlotte
Novartis Investigative Site, Asheville
Novartis Investigative Site, Columbia
Novartis Investigative Site, Greenville
Novartis Investigative Site, Canton
Novartis Investigative Site, Orlando
Novartis Investigative Site, Hialeah
Novartis Investigative Site, South Miami
Novartis Investigative Site, Miami
Novartis Investigative Site, Tamarac
Novartis Investigative Site, Tampa
Novartis Investigative Site, Largo
Novartis Investigative Site, Palm Harbor
Novartis Investigative Site, Verona
Novartis Investigative Site, Nashville
Novartis Investigative Site, Johnson City
Novartis Investigative Site, Jackson
Novartis Investigative Site, Khon Kaen
Novartis Investigative Site, Bowling Green
Novartis Investigative Site, Guadalajara
Novartis Investigative Site, Gallipolis
Novartis Investigative Site, Pieve di Coriano
Novartis Investigative Site, Florence
Novartis Investigative Site, Chiang Mai
Novartis Investigative Site, Siena
Novartis Investigative Site, Eagan
Novartis Investigative Site, Little Rock
Novartis Investigative Site, Mesquite
Novartis Investigative Site, Dallas
Novartis Investigative Site, Houston
Novartis Investigative Site, Houston
Novartis Investigative Site, Culiacán
Novartis Investigative Site, Salt Lake City
Novartis Investigative Site, Mesa
Novartis Investigative Site, Paradise Valley
Novartis Investigative Site, Peoria
Novartis Investigative Site, Las Vegas
Novartis Investigative Site, Songkhla
Novartis Investigative Site, Santa Monica
Novartis Investigative Site, Torrance
Novartis Investigative Site, Upland
Novartis Investigative Site, Stanford
Novartis Investigative Site, Catania
Novartis Investigative Site, Portland
Novartis Investigative Site, Jaipur
Novartis Investigative Site, Amravati
Novartis Investigative Site, Secunderabad
Novartis Investigative Site, Hyderabad
Novartis Investigative Site, Bangalore
Novartis Investigative Site, Bangalore
Novartis Investigative Site, Tampa
Novartis Investigative Site, Kansas City
Novartis Investigative Site, Buenos Aires
Novartis Investigative Site, Buenos Aires
Novartis Investigative Site, Caba
Novartis Investigative Site, Lanús
Novartis Investigative Site, Caba
Novartis Investigative Site, Ciudad Autonoma de Bs As
Novartis Investigative Site, Córdoba
Novartis Investigative Site, Rosario
Novartis Investigative Site, Rosario
Novartis Investigative Site, Winnipeg
Novartis Investigative Site, St. Catharines
Novartis Investigative Site, Sainte-Foy
Novartis Investigative Site, Bucaramanga
Novartis Investigative Site, Bogotá
Novartis Investigative Site, Medellín
Novartis Investigative Site, Panama City
Novartis Investigative Site, Guatemala City
Novartis Investigative Site, Guatemala City
Novartis Investigative Site, Guatemala City
Novartis Investigative Site, Székesfehérvár
Novartis Investigative Site, Veszprém
Novartis Investigative Site, Mumbai
Novartis Investigative Site, Pune
Novartis Investigative Site, New Delhi
Novartis Investigative Site, Ajmer
Novartis Investigative Site, Nagoya
Novartis Investigative Site, Nagoya
Novartis Investigative Site, Chiba
Novartis Investigative Site, Yotsukaidō
Novartis Investigative Site, Fukuoka
Novartis Investigative Site, Fukuoka
Novartis Investigative Site, Iizuka
Novartis Investigative Site, Kitakyushu
Novartis Investigative Site, Takasaki
Novartis Investigative Site, Hiroshima
Novartis Investigative Site, Sapporo
Novartis Investigative Site, Sapporo
Novartis Investigative Site, Kamakura
Novartis Investigative Site, Kawasaki
Novartis Investigative Site, Sagamihara
Novartis Investigative Site, Yokohama
Novartis Investigative Site, Kumamoto
Novartis Investigative Site, Taihaku-ku
Novartis Investigative Site, Nagano
Novartis Investigative Site, Nagasaki
Novartis Investigative Site, Sasebo
Novartis Investigative Site, Kurashiki
Novartis Investigative Site, Okayama
Novartis Investigative Site, Tsukubo-gun
Novartis Investigative Site, Hannan
Novartis Investigative Site, Kawachi-Nagano
Novartis Investigative Site, Osaka
Novartis Investigative Site, Kawagoe
Novartis Investigative Site, Tokorozawa
Novartis Investigative Site, Fuji
Novartis Investigative Site, Hamamatsu
Novartis Investigative Site, Fuchū
Novartis Investigative Site, Itabashi-ku
Novartis Investigative Site, Setagaya-ku
Novartis Investigative Site, Shinjuku-ku
Novartis Investigative Site, Shinjuku-ku
Novartis Investigative Site, Takaoka
Novartis Investigative Site, Toyama
Novartis Investigative Site, Shimonoseki
Novartis Investigative Site, Mexico City
Novartis Investigative Site, Panama City
Novartis Investigative Site, Ponce
Novartis Investigative Site, San Juan
Novartis Investigative Site, Ankara
Novartis Investigative Site, Leytonstone
Novartis Investigative Site, Cannock
Novartis Investigative Site, Salisbury
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY